The ENHANCE study and marketing ezetimibe

JAMA

Volumn 299, Issue 23, 2008, Pages 2747-

  Akdim, Fatima ^a   Kastelein, John J P ^a   Gaudet, Daniel ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ARTERIAL WALL THICKNESS; ARTERY WALL; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL RESEARCH; DISEASE COURSE; DRUG MARKETING; FAMILIAL HYPERCHOLESTEROLEMIA; HOSPITAL; LETTER; PRIORITY JOURNAL; REMISSION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; NOTE;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II;

EID: 45349083077     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.23.2747-a     Document Type: Letter

References (3)

1. Greenland P, Lloyd-Jones D. Critical lessons from the ENHANCE trial. JAMA. 2008;299(8):953-955.
2. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357(9256):577-581.
3. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292(3):331-337.